Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-13, Stock:ABBV, The news for the past five days is as follows:
2018-02-06: NEWS1: AbbVie Has Raised Its 2018 Earnings Guidance.NEWS2: Notable ETF Inflow Detected - MTUM, BA, ABBV, PYPL.NEWS3: Notable ETF Inflow Detected - MTUM, BA, ABBV, PYPL.NEWS4: Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View.NEWS5: Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View.NEWS6: Analysts’ Recommendations for AbbVie and Peers in January 2018.NEWS7: AbbVie's Imbruvica Gains 'Orphan Drug' Status.NEWS8: Centene (CNC) Beats Q4 Earnings & Revenues, Ups &apos;18 View.NEWS9: Free Post Earnings Research Report: AbbVie’s Q4 FY17 Results Beat Market Estimates.
2018-02-07: NEWS1: Wednesday's ETF with Unusual Volume: PPH.NEWS2: Wednesday's ETF with Unusual Volume: PPH.NEWS3: Add These 7 GARP Stocks to Your Portfolio for Better Returns.NEWS4: Add These 7 GARP Stocks to Your Portfolio for Better Returns.NEWS5: Humira Will Remain a Key Growth Driver for AbbVie in 2018.NEWS6: Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre.NEWS7: Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre.NEWS8: Add These 7 GARP Stocks to Your Portfolio for Better Returns.NEWS9: Why AbbVie Inc.'s Shares Rocketed 16% in January.NEWS10: Why AbbVie Inc.'s Shares Rocketed 16% in January.NEWS11: AbbVie Expected to Witness Strong Growth in Margins in 2018.NEWS12: Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter.NEWS13: Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter.NEWS14: Why AbbVie is a Top 25 Dividend Giant (ABBV).NEWS15: Why AbbVie is a Top 25 Dividend Giant (ABBV).NEWS16: Why AbbVie Inc.&apos;s Shares Rocketed 16% in January.NEWS17: Tax Cuts and Jobs Act Has Proven a Major Boon for AbbVie in 2018.NEWS18: New Research: Key Drivers of Growth for Rockwell Automation, Voya Financial, EPR Properties, Hudson Pacific Properties, AbbVie, and Ventas — Factors of Influence, Major Initiatives and Sustained Production.
2018-02-08: NEWS1: Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS2: Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS3: FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up.NEWS4: FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up.NEWS5: Venclexta May Prove a Novel Chemotherapy-Free Treatment Option.NEWS6: FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up.NEWS7: Imbruvica Leads in the Chronic Lymphocytic Leukemia Space.NEWS8: Here's What Gilead Sciences Just Said About Its Future.NEWS9: Here's What Gilead Sciences Just Said About Its Future.NEWS10: What Are the Best Healthcare Stocks to Buy? Here Are a Top AI System's 5 Favorites.NEWS11: What Are the Best Healthcare Stocks to Buy? Here Are a Top AI System's 5 Favorites.NEWS12: ABBV to Focus on Advancing Late-Stage Immunology Research in 2018.NEWS13: Here&apos;s What Gilead Sciences Just Said About Its Future.NEWS14: What Are the Best Healthcare Stocks to Buy? Here Are a Top AI System&apos;s 5 Favorites.
2018-02-09: NEWS1: What Drove Pfizer’s 4Q17 Growth?.NEWS2: Amgen’s Neulasta and Enbrel in 4Q17 and 2017.NEWS3: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS4: How Did Pfizer’s Geographical Regions Perform in 4Q17?.NEWS5: Mavyret Is Expected to Boost AbbVie’s Hepatitis C Revenue in 2018.
2018-02-12: NEWS1: Is AbbVie or Vertex Pharmaceuticals the Better Buy Now?.NEWS2: Is AbbVie or Vertex Pharmaceuticals the Better Buy Now?.NEWS3: 5 Solid Dividend Growth Stocks Amid Rising Rates.NEWS4: 5 Solid Dividend Growth Stocks Amid Rising Rates.NEWS5: Is AbbVie or Vertex Pharmaceuticals the Better Buy Now?.NEWS6: 5 Solid Dividend Growth Stocks Amid Rising Rates.NEWS7: 5 Solid Dividend Growth Stocks Amid Rising Rates.NEWS8: These 3 Drugs Are Critical to AbbVie's Success.NEWS9: These 3 Drugs Are Critical to AbbVie's Success.NEWS10: AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting.NEWS11: These 3 Drugs Are Critical to AbbVie&apos;s Success.NEWS12: Is AbbVie Inc’s (NYSE:ABBV) ROE Of 93.77% Sustainable?.

Answer: Decrease